SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: A.J. Mullen who wrote (51987)10/21/2022 2:28:09 PM
From: A.J. Mullen1 Recommendation

Recommended By
Lance Bredvold

  Read Replies (1) of 52153
 
I thought Imux had settled down, but it has been flirting with the year's low and was down 78% at one point today. Immunic (IMUX) dropped 78% today to $2.04, which takes its cap to less than cash on hand according to Yahoo. TAn interim look at a Phase 1 trial showed no separation of the treatment arm from placebo at 28 days.

It's one drug, one indication (moderate-severe psoriasis). The same drug is in Phase 1 for Prostate Cancer. Another drug is in three trials: Phase 3 for relapsing MS, Phase 2 for progressive MS and Phase 2 for another disease. Finally, they have a third drug in Phase 1 against Celiac Disease. On the otherhand, it comes after the MS drug failed a Phase 2 trial for ulcerative colitis and the company abandoned for it indication. fiercebiotech.com I guess some are worried that together they are signs of a trend.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News